Related Experiment Videos
Transforming growth factor-beta inhibits the growth of renal cell carcinoma in vitro
L G Gomella1, E R Sargent, W M Linehan
1Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892.
Abstract:
Transforming growth factor-beta (TGF-beta) is a bifunctional growth regulatory hormone which inhibits the growth of many normal and neoplastic epithelial cell lines in monolayer culture. Endogenous and exogenous TGF-beta may influence cell proliferation through autocrine and paracrine binding to specific TGF-beta receptors. Growth effects of TGF-beta on human renal cell carcinoma cell lines have not been thus far described. We have studied the effects of TGF-beta on one renal tumor-derived (UOK-39) and one established (SKRC-7) renal cell carcinoma cell line. Exogenous addition of biologically active TGF-beta to cell cultures at concentrations between two and five ng./ml. inhibited the anchorage-dependent growth of UOK-39 by 75% and SKRC-7 by 44%, relative to controls. Low numbers of high affinity TGF-beta receptors were identified on both cell lines in 125I-TGF-beta binding assays. UOK-39 cells bound radiolabeled TGF-beta with higher affinity than SKRC-7 cells, but had fewer receptor sites, by Scatchard analysis of binding data. These results suggest that TGF-beta inhibits proliferation of renal carcinoma cells in vitro which may be mediated through binding of exogenous TGF-beta to functional TGF-beta receptors on the cell surface.
Insights
Transforming growth factor-beta (TGF-beta) inhibits renal cell carcinoma growth. This hormone binds to cell surface receptors, suggesting a therapeutic target for kidney cancer.
Area of Science:
- Oncology
- Cell Biology
- Molecular Endocrinology
Background:
- Transforming growth factor-beta (TGF-beta) is a key regulator of cell growth, known to inhibit many epithelial cell types.
- TGF-beta exerts its effects via autocrine and paracrine signaling through specific cell surface receptors.
- The impact of TGF-beta on human renal cell carcinoma (RCC) proliferation and its receptor interactions were previously undescribed.
Purpose of the Study:
- To investigate the effects of TGF-beta on the growth of human renal cell carcinoma cell lines.
- To determine if TGF-beta binds to functional receptors on these cancer cells.
- To explore the potential role of TGF-beta signaling in RCC growth regulation.
Main Methods:
- Utilized two human renal cell carcinoma cell lines: UOK-39 (tumor-derived) and SKRC-7 (established).
- Administered biologically active TGF-beta to cell cultures and measured anchorage-dependent growth inhibition.
- Quantified TGF-beta receptors using 125I-TGF-beta binding assays and Scatchard analysis.
Main Results:
- Exogenous TGF-beta significantly inhibited the growth of both UOK-39 (75% inhibition) and SKRC-7 (44% inhibition) cell lines.
- Both cell lines expressed low numbers of high-affinity TGF-beta receptors.
- UOK-39 cells exhibited higher affinity binding but fewer receptor sites compared to SKRC-7 cells.
Conclusions:
- TGF-beta demonstrates potent inhibitory effects on renal cell carcinoma proliferation in vitro.
- The observed growth inhibition is likely mediated by the binding of exogenous TGF-beta to functional cell surface receptors.
- These findings suggest TGF-beta signaling as a potential therapeutic avenue for kidney cancer.